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Sunuin.
Several investigators including ourselves have shown that hydralazine can potentiate the antitumour activity of certain agents against murine tumours probably by manipulating tumour blood flow. In order to investigate the effects of admrinistration of hvdralazine on systemic and tumour drug concentrations. we have examined the plasma and tissue pharmacokinetics of the recently developed nitrosourea. Tauromustine (TCNU). The effect of hydralazine on glomerular filtration rate (GFR) in mice was also examined using inulin single injection plasma clearance. An active dose of TCNU (30 mg kg-') was administered intravenously into non-tumour bearing NMRI mice or mice bearing MAC 15A or MAC 26 subcutaneous tumours. Plasma and tissue levels of TCNU were measured by HPLC. Hydralazine significantly increased (P<.005 in all cases) the AUCs and decreased the plasma clearance of the drug. Inulin plasma clearance was decreased from 0.258 ± 0.046 ml min-' to 0.096 ± 0.017 ml min-' (a factor of 2.69) after administration of hydralazine. This decrease in GFR would explain the increased plasma half-lives of a renally cleared drug. It is likelv that the increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when administered with hydralazine. but the impact of these findings on toxicity needs to be established.
It has long been known that perfusion of experimental tumours can be manipulated by the use of vasoactive agents (Algire & Legallais. 1951) . Since the microenvironment and achievable drug concentrations in solid tumours are dependent on blood vascular supply. several studies have attempted to modify the blood flow to tumours for therapeutic benefit. A number of vasoactive agents have been shown to alter blood flow to experimental tumours (Hirst & Wood. 1989 ) but most recent studies have concentrated on the antihypertensive agent hydralazine. which has consistently been shown to decrease blood flow through experimental tumours (Stratford et al.. 1988; Chaplin & Acker. 1987 : Brown. 1987 : Siemann. 1990 Siemann. . 1991 . Hydralazine has been shown to potentiate the anti-tumour effects of Melphalan against the KHT sarcoma (Stratford et al.. 1988 ) and the chemotherapeutic agents chloro-ethyl-cyclohexyl nitrosourea (CCNU) or Mitomycin-C against the KHT sarcoma (Siemann. 1991) . This tumour potentiation is thought to be the result of manipulation of tumour blood flow and the improved anti-tumour activity reported in these publications is accompanied by only a slight or no increase in host toxicity, thereby giving a greater therapeutic index resulting in possible therapeutic benefit. Studies in this laboratory have shown that hydralazine reduces blood flow through a series of experimental colon tumours (Quinn et al., 1991a) and potentiates the efficacy of TCNU, Melphalan and ThioTEPA (Quinn et al.. 1991 b) . In addition to its effects on tumour blood flow. hydralazine is likely to have systemic effects. A preliminary study by Honess and Bleehen (1991) 
Reagents
All solvents were at HPLC grade (Rh6ne Poulenc. Manchester. England) and other reagents were of analytical grade. The internal standard N-propyl-p-hydroxybenzoate was purchased from Sigma. Triple distilled water was used throughout.
Tumour system
The development of several adenocarcinomas of the large bowel in NMRI mice from primary tumours induced by prolonged administration of 1-2-dimethyl-hydralazine has been described previously (Double et al.. 1975 : Bibby et al.. 1989 . MAC 15A ascitic tumour cells (1 x 106) were inoculated subcutaneously in the flank. Tumour fragments (approximately 1 x 2 mm) of MAC 26 were implanted subcutaneously in the flank by the use of a trocar. Tumour bearing animals were used when tumours achieved an approximate weight of I g. At this size. tumours have a well established blood vascular supply (Quinn et al.. 1991b The remaining area from k-co was taken to be CJlKelp where Cq = concentration at t.
Glomerular filtration rates
Inulin was injected into non-tumour bearing mice and measured by the method of Higashi and Peters (1950 Figure 2b . The AUC was increased from 0.625 ± 0.11 to 1.68 ± 0.35 mg h ml-' ( + I s.d.) after the administration of hydralazine therefore decreasing plasma clearance from 0.258 ± 0.046 to 0.096 + 0.017 ml min'. This represents a factor of 2.69 ± 0.29.
This study was designed to see whether the previously reported chemo-potentiation of hydralazine in MAC tumours (Quinn et al., 1991b) demonstrates that the administration of hydralazie following TCNU increases the AUC of TCNU in both tumour and normal tissues. Since the hydralazie is given 1O min after TCNU it does not incrase peak plasma levels. The inulin clarance experiment presented here shows that hydralazine at a dose of l0mg kg' decreases plasma clearance by a factor of 2.69. This impaired kidney function seen as a decrease in GFR would explain the increased half-lives of a renally cleared drug whereas the decreased hepatic blood flow previously reported by Honess and Bleehen (1991) , could have implications for a drug that is hepatically metabolised. TCNU is largely metabolsed in the liver to demethylated and de-nitrosated products (Seidegard et al., 1990) , and high levels of these metabolites are found in the urine. The decrease in GFR would probably decrease the 'tis
In conclusion, this study has shown that the administration of hydralazine after TCNU increases the AUC of TCNU in plasma. tumour and normal tissues but because of the treatment protocol does not increase peak plasma levels. This increase in AUC is likely to contribute to the increased anti-tumour effects seen previously. The administration of hydralazine decreases the GFR in NMRI mice by a factor of 2.69 and this together with other systemic effects will have implications on drug metabolism and clearance, demonstrating that altered tumour blood flow is not solely responsible for the enhanced anti-tumour activity of TCNU in this system.
